Dr. Burdelya earned her PhD in Experimental Oncology at the Blokhin Cancer Research Center in Moscow, Russia, and completed her postdoctoral research in Tumor Immunology at the Moffitt Cancer Center and Research Institute, Tampa, Florida. Before joining Roswell Park Cancer Institute, she worked as a Research Associate in the Department of Molecular Genetics at The Cleveland Clinic Foundation, Cleveland, Ohio.Dr. Burdelya is an active member of the American Association for Cancer Research and the Radiation Research Society. She is the author of over 20 peer-reviewed articles and numerous abstracts.Currently, Dr. Burdelya’s research program is focused on the development and application of immune response modulators which act through TLR5 signaling for the prevention of normal tissue injury and reduction of adverse side effects induced by radiation and chemotherapeutic agents. Associated pre-clinical studies include the use of TLR5 agonists for anticancer therapy both alone or in combination with existing anti-cancer therapies.

Development of a new approach to anti-cancer therapy based on the activation of TLR5 signaling for the prevention of normal tissue injury and reduction of adverse side effects as may be induced by local irradiation or chemotherapeutic agents with dose-limiting toxicities.